Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Transplant nephrology
Under what circumstances would you consider LDL apheresis in a kidney transplant patient with FSGS recurrence within three months of transplantation?
Related Questions
How do you approach the decision to perform preimplantation biopsies in brain-dead kidney donors?
What is your approach to treating antibody-mediated rejection in a pregnant patient with a kidney transplant?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
Has your management of post-transplant FSGS changed with the advent of new FSGS directed therapies?
What is your strategy to manage the complication of long-term immunosuppression in liver transplant recipients, specifically renal dysfunction and onset of cardiometabolic comorbidities?
Would you refer a patient for kidney only or kidney and liver transplantation if they develop advanced chronic kidney disease secondary to primary hyperoxaluria type 2?
Do you recommend plasmapheresis prior to kidney transplantation for patients with elevated panel-reactive antibody percentages?
How do you approach kidney transplant evaluation and management in an ESKD patient with a history of anti-GBM disease and currently detectable anti-GBM antibodies?
How long do you wait for a reduction in EBV viral load after reducing immunosuppression before deciding to start rituximab in a kidney transplant patient with EBV viremia?
Would you rely on virtual crossmatch alone to proceed with a kidney transplant?
